Xiaoyu Wang , Weijie Chi , Jiao Wu , Jingwen Zou , Jiyoung Yoo , Seokjin Hong , Fan Zhang , Zhiqiang Mao , Jong Seung Kim
{"title":"A NIR-II emissive sonosensitized biotuner for pyroptosis-enhanced sonodynamic therapy of hypoxic tumors","authors":"Xiaoyu Wang , Weijie Chi , Jiao Wu , Jingwen Zou , Jiyoung Yoo , Seokjin Hong , Fan Zhang , Zhiqiang Mao , Jong Seung Kim","doi":"10.1016/j.biomaterials.2024.122969","DOIUrl":null,"url":null,"abstract":"<div><div>Pyroptosis is considered as a new way to effectively boost the immune response of tumors and inhibit tumor growth. Effective strategies to induce pyroptosis mainly rely on chemotherapeutic drugs and phototherapy, but their potential biotoxicity and phototoxicity limit their application in biomedicine. Herein, we designed a NIR-II emitting pyroptosis biotuner, <strong>Rd-TTPA</strong>, which induced pyroptosis under ultrasound irradiation to achieve pyroptosis-enhanced sonodynamic therapy (SDT) and immunogenic cell death (ICD) for tumors. Benefiting from its A-π-D<sub>1</sub>-D<sub>2</sub> structure enhanced donor-acceptor interaction, <strong>Rd-TTPA</strong> can induce cell pyroptosis under both normoxia (21 % O<sub>2</sub>) and hypoxia (2 % O<sub>2</sub>) conditions by rapidly generating superoxide radicals (O<sub>2</sub><sup>−•</sup>) upon ultrasound irradiation. The sonodynamic biotuner of pyroptosis overcomes the longstanding weakness of chemical drug and photosensitizer-based pyroptosis, such as drug resistance and limited penetration depth. In-depth studies demonstrated that <strong>Rd-TTPA</strong> can selectively target tumor cell mitochondria and possess excellent <em>in vivo</em> NIR-II fluorescence imaging capabilities. Administrating a tumor-bearing mouse model with <strong>Rd-TPPA</strong>, satisfying antitumor efficacy <em>via</em> pyroptosis-augmented SDT was achieved upon the guidance of NIR-II fluorescence imaging.</div></div>","PeriodicalId":254,"journal":{"name":"Biomaterials","volume":"315 ","pages":"Article 122969"},"PeriodicalIF":12.8000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomaterials","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0142961224005040","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Pyroptosis is considered as a new way to effectively boost the immune response of tumors and inhibit tumor growth. Effective strategies to induce pyroptosis mainly rely on chemotherapeutic drugs and phototherapy, but their potential biotoxicity and phototoxicity limit their application in biomedicine. Herein, we designed a NIR-II emitting pyroptosis biotuner, Rd-TTPA, which induced pyroptosis under ultrasound irradiation to achieve pyroptosis-enhanced sonodynamic therapy (SDT) and immunogenic cell death (ICD) for tumors. Benefiting from its A-π-D1-D2 structure enhanced donor-acceptor interaction, Rd-TTPA can induce cell pyroptosis under both normoxia (21 % O2) and hypoxia (2 % O2) conditions by rapidly generating superoxide radicals (O2−•) upon ultrasound irradiation. The sonodynamic biotuner of pyroptosis overcomes the longstanding weakness of chemical drug and photosensitizer-based pyroptosis, such as drug resistance and limited penetration depth. In-depth studies demonstrated that Rd-TTPA can selectively target tumor cell mitochondria and possess excellent in vivo NIR-II fluorescence imaging capabilities. Administrating a tumor-bearing mouse model with Rd-TPPA, satisfying antitumor efficacy via pyroptosis-augmented SDT was achieved upon the guidance of NIR-II fluorescence imaging.
期刊介绍:
Biomaterials is an international journal covering the science and clinical application of biomaterials. A biomaterial is now defined as a substance that has been engineered to take a form which, alone or as part of a complex system, is used to direct, by control of interactions with components of living systems, the course of any therapeutic or diagnostic procedure. It is the aim of the journal to provide a peer-reviewed forum for the publication of original papers and authoritative review and opinion papers dealing with the most important issues facing the use of biomaterials in clinical practice. The scope of the journal covers the wide range of physical, biological and chemical sciences that underpin the design of biomaterials and the clinical disciplines in which they are used. These sciences include polymer synthesis and characterization, drug and gene vector design, the biology of the host response, immunology and toxicology and self assembly at the nanoscale. Clinical applications include the therapies of medical technology and regenerative medicine in all clinical disciplines, and diagnostic systems that reply on innovative contrast and sensing agents. The journal is relevant to areas such as cancer diagnosis and therapy, implantable devices, drug delivery systems, gene vectors, bionanotechnology and tissue engineering.